<DOC>
	<DOCNO>NCT00849082</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x ray kill tumor cell . This may effective treatment prostate cancer . Androgens cause growth prostate cancer cell . Antihormone therapy , goserelin cyproterone , may lessen amount androgen make body reduces amount androgen available body . It yet know whether radiation therapy alone effective radiation therapy give together goserelin cyproterone treat patient prostate cancer . PURPOSE : This randomized phase III trial study radiation therapy see well work compare give radiation therapy together goserelin cyproterone treat patient prostate cancer high risk metastasis .</brief_summary>
	<brief_title>Radiation Therapy With Without Goserelin Cyproterone Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate ability adjuvant hormone therapy LHRH agonist ( Goserelin depot ) produce increase disease-free survival prolong overall survival initiate first week radiotherapy prostatic cancer patient high risk develop metastatic disease . OUTLINE : Randomized study . Arm I : Radiotherapy . Whole-pelvic irradiation use photon recommend energy least 10 MV ( Co60 therapy acceptable high energy unavailable ) . Arm II : Radiotherapy plus 2-Drug Combination Hormonal Therapy . Whole-pelvic irradiation Arm I ; plus Goserelin , ZDX , NSC-606864 ; Cyproterone acetate , CPTR , NSC-81430 . PROJECTED ACCRUAL : 400 patient enter 5 year . At least 75 patient arm follow relapse .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven prostatic adenocarcinoma follow TNM stage WHO grade : T1 T2 grade G3 T3 T4 histologic grade No evidence distant metastases No evidence positive common iliac paraaortic lymph node Confirmed bone scan , chest xray , negative ultrasound CT liver , CT retroperitoneum and/or bipedal lymphangiography Extraperitoneal pelvic lymph node biopsy may either positive negative provide stage grade criterion meet PATIENT CHARACTERISTICS : Age : Under 80 Performance status : WHO 02 Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No history second malignancy except basal cell skin carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : No prior hormonal therapy prostate cancer Radiotherapy : No prior radiotherapy prostate cancer Surgery : No prior radical prostatectomy No prior transperitoneal lymph node stag</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>